Patents Assigned to Eurand Pharmaceuticals Ltd.
-
Patent number: 8545881Abstract: A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drug, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.Type: GrantFiled: April 19, 2004Date of Patent: October 1, 2013Assignee: Eurand Pharmaceuticals, Ltd.Inventors: Gopi M. Venkatesh, Ken Kangyi Qian, Shyam Vangala, James M. Clevenger, Donald Guenther
-
Patent number: 7951399Abstract: A process is described for the activation (increase in solubility and bioavailability) of drugs. The process, carried out in a vibrational mill, is characterised by the use of given proportions between the physical mixture made up of drug and pharmaceutical carrier and the empty volume among the grinding means contained inside the mill. The process leads to obtaining powders for pharmaceutical use in which the drug has a high and constant degree of activation; this result is obtainable irrespective of the nature of the drug and carrier used, and of their weight ratio.Type: GrantFiled: June 27, 2002Date of Patent: May 31, 2011Assignee: Eurand Pharmaceuticals Ltd.Inventors: Luca Dobetti, Massimo Bresciani
-
Publication number: 20110123605Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: ApplicationFiled: February 2, 2011Publication date: May 26, 2011Applicant: EURAND PHARMACEUTICALS LTDInventors: Giovanni ORTENZI, Marco Marconi, Luigi Mapelli
-
Publication number: 20110123633Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: ApplicationFiled: February 2, 2011Publication date: May 26, 2011Applicant: EURAND PHARMACEUTICALS LTDInventors: Giovanni ORTENZI, Marco Marconi, Luigi Mapelli
-
Publication number: 20110123634Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: ApplicationFiled: February 2, 2011Publication date: May 26, 2011Applicant: EURAND PHARMACEUTICALS LTDInventors: Giovanni ORTENZI, Marco Marconi, Luigi Mapelli
-
Publication number: 20100270183Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: ApplicationFiled: July 8, 2010Publication date: October 28, 2010Applicant: EURAND PHARMACEUTICALS LTDInventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
-
Patent number: 7793871Abstract: The invention comprises a process for activating drugs by means of high-energy co-grinding of the drug with a pharmaceutical carrier, characterized by the use of a vibrational mill equipped with means that regulate the vibration frequency. The process, performed by modifying the frequency of vibration and keeping its amplitude constant, produces drug/carrier composites with a constant particle size in which the degree of drug activation increases in proportion to the frequency applied. The invention also includes a vibrational mill suitably modified to perform the process described.Type: GrantFiled: June 25, 2008Date of Patent: September 14, 2010Assignee: Eurand Pharmaceuticals Ltd.Inventors: Luca Dobetti, Leonardo Rabaglia, Massimo Bresciani
-
Patent number: 7658918Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.Type: GrantFiled: October 9, 2009Date of Patent: February 9, 2010Assignee: Eurand Pharmaceuticals Ltd.Inventors: Giovanni Ortenzi, Marco Marconi, Luigi Mapelli
-
Publication number: 20090253651Abstract: New drug delivery systems (DDS) are described containing hyaluronic acid and a therapeutic agent, wherein the therapeutic agent is linked, directly or via a linker, to 6-aminohyaluronic acid and where the linkage of the drug or linker with 6-aminohyaluronic acid is realised by an amide bond. Preferred therapeutic agents for use in the present DDS are anti-inflammatory, antibiotic, antitumor drugs. Preferred linkers are: succinic acid, succinic acid linked to aminoacids, succinic acid linked to peptides. The DDS are stable and free of undesired reaction by-products and impurities, and show a high level of pharmacological efficacy.Type: ApplicationFiled: July 27, 2007Publication date: October 8, 2009Applicant: EURAND PHARMACEUTICALS LTD.Inventors: Stefano Norbedo, Susanna Bosi, Massimo Bergamin, Riaz Ahmed Khan, Erminio Murano, Francesca Dinon
-
Publication number: 20090197797Abstract: The present invention refers to a drug delivery system consisting of hyaluronic acid and a therapeutic active agent.Type: ApplicationFiled: January 25, 2007Publication date: August 6, 2009Applicant: EURAND PHARMACEUTICALS LTD.Inventors: Stefano Norbedo, Susanna Bosi, Massimo Bergamin, Riaz Ahmed Khan, Erminio Murano
-
Publication number: 20080251615Abstract: The invention comprises a process for activating drugs by means of high-energy co-grinding of the drug with a pharmaceutical carrier, characterised by the use of a vibrational mill equipped with means that regulate the vibration frequency. The process, performed by modifying the frequency of vibration and keeping its amplitude constant, produces drug/carrier composites with a constant particle size in which the degree of drug activation increases in proportion to the frequency applied. The invention also includes a vibrational mill suitably modified to perform the process described.Type: ApplicationFiled: June 25, 2008Publication date: October 16, 2008Applicant: EURAND PHARMACEUTICALS LTD.Inventors: Luca Dobetti, Leonardo Rabaglia, Massimo Bresciani
-
Patent number: 7049434Abstract: The invention describes new hyaluronan derivatives where the hydroxyl groups are esterified or carbamoylated in amounts ranging from 0.01% to 100% and the carboxyl groups are either totally or partially esterified with alcohols or are in the form of salt.Type: GrantFiled: June 3, 2002Date of Patent: May 23, 2006Assignee: Eurand Pharmaceuticals Ltd.Inventors: Paolo Mariotti, Luciano Navarini, Luca Stucchi, Vladimir Vinkovic, Vitomir {hacek over (S)}unjić
-
Patent number: 6897203Abstract: The present invention relates to polysaccharidic esters of retinoic acid, wherein the hydroxyl groups of the monosaccharidic units of the polysaccharide are partially or totally esterified with retinoic acid. A process to obtain these esters is also described. The products according to the present invention can be used in the pharmaceutical and cosmetic field.Type: GrantFiled: January 16, 2002Date of Patent: May 24, 2005Assignee: Eurand Pharmaceuticals Ltd.Inventors: Alessandro Rastrelli, Giuliana Miglierini, Alberto Perbellini, Luca Stucchi
-
Patent number: 6844328Abstract: The present invention is related to polysaccharide esters of N-derivatives of glutamic acid (N-GA derivatives). These polysaccharidic esters have antiproliferative activity and are characterized by a low systemic toxicity. The esters of the invention are used in the prevention and therapy of diseases caused by cellular hyperproliferation, particularly psoriasis, tumors, rheumatoid arthritis, or intestinal inflammatory pathologies.Type: GrantFiled: March 16, 2001Date of Patent: January 18, 2005Assignee: Eurand Pharmaceuticals Ltd.Inventors: Giuliana Miglierini, Luca Stucchi, Alessandro Rastrelli
-
Patent number: 6663888Abstract: A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity/manifestation of gastric acid secretion (and/or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.Type: GrantFiled: January 25, 2002Date of Patent: December 16, 2003Assignee: Eurand Pharmaceuticals Ltd.Inventors: Philip J. Percel, Nehal H. Vyas, Krishna S. Vishnupad, Gopi M. Venkatesh
-
Patent number: 6627223Abstract: A pharmaceutical dosage form such as a capsule capable of delivering therapeutic agents into the body in a time-controlled or position-controlled pulsatile release fashion, is composed of a multitude of multicoated particulates (beads, pellets, granules, etc.) made of one or more populations of beads. Each of these beads except an immediate release bead has at least two coated membrane barriers. One of the membrane barriers is composed of an enteric polymer while the second membrane barrier is composed of a mixture of water insoluble polymer and an enteric polymer. The composition and the thickness of the polymeric membrane barriers determine the lag time and duration of drug release from each of the bead populations. Optionally, an organic acid containing intermediate membrane may be applied for further modifying the lag time and/or the duration of drug release.Type: GrantFiled: February 7, 2001Date of Patent: September 30, 2003Assignee: Eurand Pharmaceuticals Ltd.Inventors: Phillip Percel, Krishna S. Vishnupad, Gopi M. Venkatesh
-
Patent number: 6500454Abstract: A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration—time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.Type: GrantFiled: October 4, 2001Date of Patent: December 31, 2002Assignee: Eurand Pharmaceuticals Ltd.Inventors: Phillip J. Percel, Krishna S. Vishnupad, Gopi M. Venkatesh
-
Patent number: 6451345Abstract: The present invention provides taste-masked microcapsules of Linezolid or the like (any member of the orally effective oxazolidinone or macrolide antibiotics), suitable for oral administration as a suspension, a fast-disintegrating, effervescent or chewable tablet, and more specifically relates to such oral dosage forms in which the bitter taste of Linezolid contained therein is masked by a combination of microencapsulation by solvent coacervation and subsequent functional membrane coating on said microcapsules. The taste-masked granules thus obtained release less than 5%, most preferably less than 3%, at a pH of 4.0 to 6.0 (pH of the saliva) but rapidly release (as a burst) at pHs of the upper intestinal tract. The taste-masked granules are optionally blended with other pharmaceutically acceptable excipients and filled into unit dose containers or compressed into fast-disintegrating/effervescent/chewable tablets.Type: GrantFiled: February 17, 2000Date of Patent: September 17, 2002Assignee: Eurand Pharmaceuticals Ltd.Inventors: Phillip J. Percel, Krishna S. Vishnupad, Gopi M. Venkatesh